'To switch or not to switch: That is the question'-More than 10% of ratio at 3 months: How to treat chronic myeloid leukemia patients with this response?

摘要

The long-term follow-up of IRIS study showed that rates of events and progression were increased during the first 3 years of treatment [1]. This evidence pushed us to search for other strategies of treatment, including higher doses and drug combinations of imatinib; however, these approaches failed to demonstrate a reduction of the events rate and led to identification of new time points of patients monitoring with the aim to identify when switching to second generation inhibitors and rescuing non-optimal responders.